financetom
Business
financetom
/
Business
/
Engineering Services Company Jacobs Solutions Tightens FY24 EPS Forecast: Details Here
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Engineering Services Company Jacobs Solutions Tightens FY24 EPS Forecast: Details Here
Aug 6, 2024 7:37 AM

Jacobs Solutions Inc. ( J ) shares are trading higher after it reported third-quarter FY24 results.

Revenue was $4.23 billion, beating the consensus of $3.99 billion. Adjusted EPS totaled $1.96, which was in line with the consensus.

Jacobs’ CEO Bob Pragada said, “This quarter, we made significant strides in our portfolio optimization, focusing on high-growth sectors that emphasize sustainability and infrastructure resilience. Our bookings and backlog remain strong, demonstrating the trust our clients place in our ability to deliver innovative solutions for complex challenges.”

The backlog in the quarter under review was $30.6 billion, up 6% Y/Y. Gross profit in backlog was up 5.5% Y/Y.

The company registered cash flow from operations of $483 million in the quarter. The company bought back shares worth $151 million in the quarter. Cash and cash equivalents at the end of the period totaled $1.21 billion.

Jacobs’ CFO Venk Nathamuni added, “We continue to focus on operational excellence and expect to end fiscal year 2024 with strong profitability. With the anticipated completion of the planned spin-off in the coming months, we are excited to share our enhanced strategic plan for Jacobs following the anticipated separation at our next Investor Day on February 18, 2025 in Miami, Florida.”

FY24 Outlook: Jacobs Solutions ( J ) reiterated its outlook for adjusted EBITDA at $1.540 billion-$1.585 billion and revised adjusted EPS outlook to $7.85 to $8.05 (from $7.80 to $8.10 prior) vs. the consensus of $8.03.

Investors can gain exposure to the stock via Tidal ETF Trust Newday Ocean Health ETF and Valued Advisers Trust Kovitz Core Equity ETF .

Price Action: J shares are up 1.81% at $142.66 at the last check Tuesday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MoonLake Immunotherapeutics Shares Slightly Up Despite Wider Q2 Loss
MoonLake Immunotherapeutics Shares Slightly Up Despite Wider Q2 Loss
Aug 7, 2024
10:38 AM EDT, 08/07/2024 (MT Newswires) -- MoonLake Immunotherapeutics ( MLTX ) shares were slightly up in recent Wednesday trading despite posting a wider Q2 net loss from a year earlier. The biotechnology company reported a Q2 loss of $0.39 per share, widening from a loss of $0.23 a year earlier. Analysts polled by Capital IQ expected a loss of...
Wolverine Shares Fall as Company Posts Lower Q2 Adjusted EPS, Revenue
Wolverine Shares Fall as Company Posts Lower Q2 Adjusted EPS, Revenue
Aug 7, 2024
10:37 AM EDT, 08/07/2024 (MT Newswires) -- Wolverine World Wide ( WWW ) shares were down 1.7% in recent Wednesday trading after the company reported Q2 adjusted earnings of $0.15 per diluted share, down from $0.19 a year earlier. Analysts polled by Capital IQ expected $0.11. Total revenue for the quarter ended June 29 was $425.2 million, down from $589.1...
Genpact Names Sanjeev Vohra Chief Technology, Innovation Officer
Genpact Names Sanjeev Vohra Chief Technology, Innovation Officer
Aug 7, 2024
10:39 AM EDT, 08/07/2024 (MT Newswires) -- Genpact ( G ) said Wednesday it has appointed Sanjeev Vohra as its first chief technology and innovation officer, effective immediately. Vohra, who has more than 30 years of experience, most recently served as global lead of Accenture Applied Intelligence, the company said. Shares of Genpact ( G ) rose more than 1%...
NewAmsterdam Pharma Q2 Net Loss Narrows, Revenue Rises; Shares Lower
NewAmsterdam Pharma Q2 Net Loss Narrows, Revenue Rises; Shares Lower
Aug 7, 2024
10:37 AM EDT, 08/07/2024 (MT Newswires) -- NewAmsterdam Pharma ( NAMS ) shares were about 1.8% lower in early trading Wednesday after the late-stage biopharmaceutical company narrowed its Q2 loss amid higher revenue. The firm reported a Q2 net loss of $0.41 per diluted share, narrower than a net loss of $0.47 per share a year earlier. Analysts polled by...
Copyright 2023-2026 - www.financetom.com All Rights Reserved